Low-molecular-weight heparins in ischemic heart disease

Current Opinion in Cardiology

Volumn 19, Issue 4, 2004, Pages 309-316

  Yan, Andrew T ^a   Goodman, Shaun G ^a,b  

^a CANADIAN HEART RESEARCH CENTRE   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Acute coronary syndrome; Fibrinolysis; Low molecular weight heparin; Unfractionated heparin

Indexed keywords

ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

CORRELATION ANALYSIS; DEATH; DRUG EFFECT; DRUG SAFETY; FIBRINOLYSIS; FRACTIONATION; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; PATENT; PRIORITY JOURNAL; REVIEW; ST SEGMENT ELEVATION; TECHNIQUE;

ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ELECTROCARDIOGRAPHY; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 3142753510     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hco.0000129665.55707.f6     Document Type: Review

References (42)

1. Braunwald E, Antman EM, Beasley JW, et al.: ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 2002, 106:1893-1900.
2. Ryan TJ, Antman EM, Brooks NH, et al.: 1999 Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 1999, 100:1016-1030.
3. Hirsh J, Warkentin TE, Shaughnessy SG, et al.: Heparin and low-molecular heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Chest 2001, 119:64S-94S.
4. Budaj A, Brieger D, Steg PG, et al.: Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE). Am Heart J 2003, 146:999-1006. A prospective, multinational, observational study examining the geographic and practice variation in the use of antiplatelet and antithrombotic therapies in 12,665 patients with ACS.
5. Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group: Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996, 347:561-568.
6. The FRAXIS Study Group: Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q-wave myocardial infarction: FRAXIS (FRAXiparine in Ischemic Syndrome). Eur Heart J 1999, 20:1553-1562.
7. Klein W, Buchwald A, Hillis SE, et al.: Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation 1997, 96:61-68.
8. Cohen M, Demers C, Gurfinkel EP, et al.: For the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group: A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997, 337:447-452.
9. Antman EM, McCabe CH, Gurfinkel EP, et al.: For the TIMI 11B Investigators. Enoxaparin for the acute and chronic management of unstable angina/non-Q wave myocardial infarction: results of TIMI 11B. Circulation 1999, 100:1593-1601.
10. Borja J: Role of low-molecular-weight heparin in the management of acute coronary syndromes. Curr Opin Cardiol 2002, 17:608-612.
11. Cohen M: The role of low-molecular-weight heparin in the management of acute coronary syndromes. J Am Coll Cardiol 2003, 41:55S-61S.
12. Eikelboom JW, Anand SS, Malmberg K, et al.: Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000, 355:1936-1942.
13. Antman EM, Cohen M, Radley D, et al.: Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis. Circulation 1999, 100:1602-1608.
14. Antman EM, Cohen M, McCabe C, et al.: Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE. Eur Heart J 2002, 23:308-314.
15. Antman EM, Cohen M, Bernink PJLM, et al.: The TIMI Risk Score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000, 284:835-842.
16. Michails LK, Katsouras CS, Papamichael N, et al.: Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial. Am Heart J 2003, 146:304-310. A randomized, open-label (with blinded outcome assessment), head-to-head comparison of enoxaparin versus tinzaparin for ACS.
17. Spinier SA, Inverso SM, Cohen M, et al.: Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J 2003, 146:33-41. A combined ESSENCE and TIMI 11B analysis of the safety and efficacy of standard-dose enoxaparin among obese patients and those with renal dysfunction.
18. Bijsterveld NR, Moons AH, Meijers JCM, et al.: The impact on coagulation of an intravenous loading dose in addition to a subcutaneous regimen of low-molecular-weight heparin in the initial treatment of acute coronary syndromes. J Am Coll Cardiol 2003, 42:424-427. A randomized study examining the temporal effect of an additional intravenous loading dose of enoxaparin on coagulation pathways in patients with ACS during the first 24 hours of treatment.
19. Boersma E, Harrington RA, Moliterno DJ, et al.: Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomized clinical trials. Lancet 2002, 359:189-198.
20. Mukherjee D, Mahaffey K, Moliterno DJ, et al.: Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B). Am Heart J 2002, 144:995-1002.
21. James S, Armstrong P, Califf R, et al.: Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes. Eur Heart J 2002, 23:1538-1545.
22. Ferguson JJ, Antman EM, Bates ER, et al.: Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Am Heart J 2003, 146:628-634. A prospective observational study of the safety and efficacy of enoxaparin in patients with ACS given concurrent glycoprotein IIb/IIIa inhibitors.
23. Cohen M, Théroux P, Borzak S, et al.: Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. Am Heart J 2002, 144:470-477.
24. Goodman SG, Fitchett D, Armstrong PW, et al.: Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes re-ceiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 2003, 107:238-244. A randomized clinical trial comparing enoxaparin with unfractionated heparin in addition to eptifibatide in 746 patients with unstable angina or non-ST-elevation myocardial infarction, which also provided mechanistic insights into the benefit of enoxaparin.
25. Goodman SG, Barr A, Sobtchouk A, et al.: Low molecular weight heparin decreases rebound ischemia in unstable angina or non-Q wave myocardial infarction: the Canadian ESSENCE ST segment monitoring substudy. J Am Coll Cardiol 2000, 36:1507-1513.
26. Blazing MA, De Lemos JA, Dyke CK, et al.: The A-to-Z trial: methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. Am Heart J 2001, 142:211-217.
27. Blazing M: Aggrastat to Zocor (A-to-Z) study: preliminary results presented at the American College of Cardiology 2003 Annual Scientific Sessions, Chicago, IL. March 2003. Available at http://www.theheart.org
28. The SYNERGY Executive Committee: The SYNERGY trial: study design and rationale. Am Heart J 2002, 143:952-960.
29. Mahaffey K, Ferguson JJ: Superior Yield of the New strategy of Enoxaparin, Revascularization, and GIY coprotein IIb/IIIa inhibitors (SYNERGY) trial: preliminary results presented at the American College of Cardiology 2004 Annual Scientific Sessions, New Orleans, LA. March 2004. Available at http://www.theheart.org
30. Kontny F, Dale J, Abildgaard U, et al.: Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. J Am Coll Cardiol 1997, 30:962-969.
31. Frostfeldt G, Ahlberg G, Gustafsson G, et al.: Low molecular weight heparin (dalteparin) as adjuvant treatment to thrombolysis in acute myocardial infarction- a pilot study: Biochemical Markers in Acute Coronary Syndromes (BIOMACS II). J Am Coll Cardiol 1999, 33:627-633.
32. Ross AM, Molhoek P, Lundergan C, et al.: Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin-second trial of heparin and aspirin reperfusion therapy (HART II). Circulation 2001, 104:648-652.
33. Baird SH, Menown IBA, McBride SJ, et al.: Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction. Eur Heart J 2002, 23:627-632.
34. Simoons ML, Krzeminska-Pakula M, Alonso A, et al.: Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction - the AMI-SK study. Eur Heart J 2002, 23:1282-1290.
35. Antman EM, Louwerenburg HW, Baars HF, et al.: Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 trial. Circulation 2002, 105:1642-1649.
36. Wallentin L, Bergstrand L, Dellborg M, et al.: Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction - the ASSENT Plus study. Eur Heart J 2003, 24:897-908. Randomized trial comparing dalteparin with unfractionated heparin as adjunct to alteplase using coronary angiographic endpoint.
37. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen: (ASSENT-3) Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001, 358:605-613.
38. Dubois CL, Belmans A, Granger CB, et al.: Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab. J Am Coll Cardiol 2003, 42:1178-1185. An analysis of the clinical outcome of patients who underwent percutaneous coronary intervention after fibrinolysis in ASSENT-3.
39. Armstrong FW, Wagner G, Goodman SG, et al.: ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction. Eur Heart J 2003, 24:1515-1522. An ASSENT-3 substudy to evaluate the course and stability of ST-segment resolution in each of the three treatment regimens, and their relationship to clinical outcome.
40. Théroux P, Welsh RC: Meta-analysis of randomized trials comparing enoxaparin versus unfractionated heparin as adjunctive therapy to fibrinolysis in ST-elevation acute myocardial infarction. Am J Cardiol 2003, 91:860-864. A meta-analysis of six randomized trials involving 6069 patients that compared enoxaparin with unfractionated heparin as adjunct antithrombotic therapy to fibrinolysis.
41. Wallentin L, Goldstein P, Armstrong PW, et al.: Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 2003, 108:135-142. A randomized trial examining the feasibility, efficacy, and safety of enoxaparin with tenecteplase in the prehospital setting.
42. Cohen M, Gensini GF, Maritz F, et al.: The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial. J Am Coll Cardiol 2003, 42:1348-1356. A randomized, double-blind trial comparing enoxaparin with unfractionated heparin in the treatment of patients with ST-elevation myocardial infarction ineligible for perfusion therapy.